Which has better earnings and valuation, EXEL or GRAL?

Exelixis has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.44B 5.71 $782.57M $3.18 17.65 GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A

Is EXEL or GRAL more profitable?

Exelixis has a net margin of 35.33% compared to GRAIL's net margin of -236.95%. Exelixis' return on equity of 42.17% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% GRAIL -236.95% -15.88% -14.02%

Does the media favor EXEL or GRAL?

In the previous week, Exelixis had 17 more articles in the media than GRAIL. MarketBeat recorded 26 mentions for Exelixis and 9 mentions for GRAIL. GRAIL's average media sentiment score of 0.96 beat Exelixis' score of 0.67 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GRAL or BMRN?

BioMarin Pharmaceutical has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A BioMarin Pharmaceutical $3.22B 3.95 $348.90M $0.37 177.51

Does the media prefer GRAL or BMRN?

In the previous week, BioMarin Pharmaceutical had 10 more articles in the media than GRAIL. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 9 mentions for GRAIL. GRAIL's average media sentiment score of 0.96 beat BioMarin Pharmaceutical's score of 0.77 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GRAL or MDGL?

Madrigal Pharmaceuticals has higher revenue and earnings than GRAIL. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A Madrigal Pharmaceuticals $958.40M 12.88 -$288.28M -$12.89 N/A

Does the media prefer GRAL or MDGL?

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than GRAIL. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 9 mentions for GRAIL. GRAIL's average media sentiment score of 0.96 beat Madrigal Pharmaceuticals' score of 0.82 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GRAL or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than GRAIL. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 9 mentions for GRAIL. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat GRAIL's score of 0.96 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, GRAL or HALO?

Halozyme Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A Halozyme Therapeutics $1.40B 8.71 $316.89M $3.35 32.00

Does the media prefer GRAL or HALO?

In the previous week, Halozyme Therapeutics had 4 more articles in the media than GRAIL. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 9 mentions for GRAIL. Halozyme Therapeutics' average media sentiment score of 1.20 beat GRAIL's score of 0.96 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GRAIL (GRAL) Competitors

$76.23 -1.33 (-1.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$76.73 +0.50 (+0.66%)

As of 09/11/2026 07:30 PM Eastern

Compare

GRAL vs. EXEL, BMRN, MDGL, ARWR, and HALO

Should you buy GRAIL stock or one of its competitors? GRAIL's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Arrowhead Pharmaceuticals (ARWR), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GRAIL compare to Exelixis?

Exelixis (NASDAQ:EXEL) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Exelixis has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market.

Exelixis has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A

In the previous week, Exelixis had 17 more articles in the media than GRAIL. MarketBeat recorded 26 mentions for Exelixis and 9 mentions for GRAIL. GRAIL's average media sentiment score of 0.96 beat Exelixis' score of 0.67 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 1.8% of GRAIL shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to GRAIL's net margin of -236.95%. Exelixis' return on equity of 42.17% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
GRAIL	-236.95%	-15.88%	-14.02%

Exelixis presently has a consensus price target of $50.07, indicating a potential downside of 10.79%. GRAIL has a consensus price target of $71.11, indicating a potential downside of 6.72%. Given GRAIL's stronger consensus rating and higher possible upside, analysts clearly believe GRAIL is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

Exelixis beats GRAIL on 11 of the 16 factors compared between the two stocks.

How does GRAIL compare to BioMarin Pharmaceutical?

GRAIL (NASDAQ:GRAL) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 1.8% of GRAIL shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GRAIL has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 10 more articles in the media than GRAIL. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 9 mentions for GRAIL. GRAIL's average media sentiment score of 0.96 beat BioMarin Pharmaceutical's score of 0.77 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

GRAIL presently has a consensus target price of $71.11, suggesting a potential downside of 6.72%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 35.77%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

BioMarin Pharmaceutical has a net margin of 2.14% compared to GRAIL's net margin of -236.95%. BioMarin Pharmaceutical's return on equity of 5.32% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51

Summary

BioMarin Pharmaceutical beats GRAIL on 13 of the 17 factors compared between the two stocks.

How does GRAIL compare to Madrigal Pharmaceuticals?

GRAIL (NASDAQ:GRAL) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

GRAIL has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market.

Madrigal Pharmaceuticals has a net margin of -25.32% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Madrigal Pharmaceuticals has higher revenue and earnings than GRAIL. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

GRAIL currently has a consensus price target of $71.11, suggesting a potential downside of 6.72%. Madrigal Pharmaceuticals has a consensus price target of $699.64, suggesting a potential upside of 30.90%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than GRAIL. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 9 mentions for GRAIL. GRAIL's average media sentiment score of 0.96 beat Madrigal Pharmaceuticals' score of 0.82 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Madrigal Pharmaceuticals beats GRAIL on 9 of the 17 factors compared between the two stocks.

How does GRAIL compare to Arrowhead Pharmaceuticals?

GRAIL (NASDAQ:GRAL) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

GRAIL has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than GRAIL. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 9 mentions for GRAIL. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat GRAIL's score of 0.96 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRAIL presently has a consensus target price of $71.11, suggesting a potential downside of 6.72%. Arrowhead Pharmaceuticals has a consensus target price of $99.15, suggesting a potential upside of 19.68%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Arrowhead Pharmaceuticals has higher revenue and earnings than GRAIL. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A
Arrowhead Pharmaceuticals	$669.50M	17.43	-$1.63M	-$2.25	N/A

Summary

Arrowhead Pharmaceuticals beats GRAIL on 11 of the 17 factors compared between the two stocks.

How does GRAIL compare to Halozyme Therapeutics?

GRAIL (NASDAQ:GRAL) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GRAIL presently has a consensus price target of $71.11, indicating a potential downside of 6.72%. Halozyme Therapeutics has a consensus price target of $91.20, indicating a potential downside of 14.93%. Given GRAIL's higher possible upside, equities analysts plainly believe GRAIL is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has a net margin of 24.86% compared to GRAIL's net margin of -236.95%. Halozyme Therapeutics' return on equity of 260.98% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Halozyme Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00

GRAIL has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 4 more articles in the media than GRAIL. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 9 mentions for GRAIL. Halozyme Therapeutics' average media sentiment score of 1.20 beat GRAIL's score of 0.96 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats GRAIL on 13 of the 17 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAL vs. The Competition

Export

Metric	GRAIL	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.46B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-7.82	14.18	274.10	25.29
Price / Sales	20.60	1,477.55	655.45	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.15	15.12	10.33	6.20
Net Income	-$408.35M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-5.12%	-4.35%	-3.33%	-2.35%
1 Month Performance	10.57%	-0.03%	-0.41%	-2.77%
1 Year Performance	100.39%	40.63%	19.22%	7.63%

GRAIL Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAL GRAIL	0.6883 of 5 stars	$76.23 -1.7%	$71.11 -6.7%	+97.2%	$3.46B	$165.26M	N/A	910	Analyst Upgrade
EXEL Exelixis	2.4957 of 5 stars	$54.64 +0.3%	$50.07 -8.4%	+43.6%	$13.49B	$2.32B	17.18	1,077	Trending News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6243 of 5 stars	$65.23 +0.9%	$88.92 +36.3%	+17.5%	$12.52B	$3.22B	176.30	3,221	Analyst Forecast
MDGL Madrigal Pharmaceuticals	3.2798 of 5 stars	$540.03 +1.2%	$699.64 +29.6%	+21.6%	$12.33B	$958.40M	N/A	90	News Coverage Insider Trade
ARWR Arrowhead Pharmaceuticals	2.5237 of 5 stars	$82.39 -3.0%	$98.42 +19.5%	+178.8%	$11.96B	$829.45M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAL) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRAIL (GRAL) Competitors

GRAL vs. EXEL, BMRN, MDGL, ARWR, and HALO

How does GRAIL compare to Exelixis?

Summary

How does GRAIL compare to BioMarin Pharmaceutical?

Summary

How does GRAIL compare to Madrigal Pharmaceuticals?

Summary

How does GRAIL compare to Arrowhead Pharmaceuticals?

Summary

How does GRAIL compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRAIL (GRAL) Competitors

GRAL vs. EXEL, BMRN, MDGL, ARWR, and HALO

How does GRAIL compare to Exelixis?

Which has more risk & volatility, EXEL or GRAL?

Which has better earnings and valuation, EXEL or GRAL?

Does the media favor EXEL or GRAL?

Do institutionals and insiders believe in EXEL or GRAL?

Is EXEL or GRAL more profitable?

Do analysts recommend EXEL or GRAL?

Summary

How does GRAIL compare to BioMarin Pharmaceutical?

Do insiders and institutionals have more ownership in GRAL or BMRN?

Which has more volatility & risk, GRAL or BMRN?

Does the media prefer GRAL or BMRN?

Do analysts prefer GRAL or BMRN?

Is GRAL or BMRN more profitable?

Which has stronger earnings & valuation, GRAL or BMRN?

Summary

How does GRAIL compare to Madrigal Pharmaceuticals?

Which has more risk and volatility, GRAL or MDGL?

Is GRAL or MDGL more profitable?

Which has better valuation & earnings, GRAL or MDGL?

Do analysts prefer GRAL or MDGL?

Do insiders & institutionals have more ownership in GRAL or MDGL?

Does the media prefer GRAL or MDGL?

Summary

How does GRAIL compare to Arrowhead Pharmaceuticals?

Do insiders and institutionals have more ownership in GRAL or ARWR?

Is GRAL or ARWR more profitable?

Which has more risk and volatility, GRAL or ARWR?

Does the media prefer GRAL or ARWR?

Do analysts rate GRAL or ARWR?

Which has better earnings & valuation, GRAL or ARWR?

Summary

How does GRAIL compare to Halozyme Therapeutics?

Do insiders & institutionals believe in GRAL or HALO?

Do analysts recommend GRAL or HALO?

Is GRAL or HALO more profitable?

Which has preferable earnings & valuation, GRAL or HALO?

Which has more risk & volatility, GRAL or HALO?

Does the media prefer GRAL or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools